ArticleMolecular cancer therapeutics2016

EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.

James P De Andrade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.